SoCalBio Networking Forum: Will 3D & 4D Printing Accelerate Device Innovation?
Thu, April 30, 4pm – 7pm
Calit2 Auditorium, University of California Irvine - 4100 Calit2 Building - Irvine, CA 92697-2800
We are pleased to announce that Dr. Ulo Palm, Senior Vice President and Head Global Brands Drug Development Operations at Actavis (now Allergan) will provide an update during the SoCalBio Networking Forum on the status on the Actavis/Allergan integration. The acquisition of Allergan by Actavis valued at approximately $70.5 billion is the largest M&A deal in Southern California's Bioscience industry. Actavis is now the second largest biopharma employer in the Greater Los Angeles region (following Amgen) with R&D and manufacturing facilities in Irvine, Corona, Riverside, Carpinteria and Santa Barbara.
Dr. Palm's update will be followed by presentations and discussion on how 3D & 4D printing can accelerate device innovations. As the medtech industry continues to face changing regulatory and reimbursement concerns, device companies have to explore new technologies promising to foster innovation, improve efficiency and accelerate pathway to market. One of these is 3-D printing, "a process of making three dimensional solid objects from a digital file. The creation of a 3D printed object is achieved using additive processes. In an additive process an object is created by laying down successive layers of material until the entire object is created (see: 3dprinting.com)." 4-D printing is 3-D printing with the added capability of device self-assembly or its embedded transformation from one shape to another, directly off the print-bed.
This SoCalBio Networking Forum will explore the potential of 3-D and 4-D printing and their various applications in medical device design and manufacturing.